Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

Mucopolysaccharidoses in Taiwan

  • Received : 2018.05.14
  • Accepted : 2018.06.09
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Mucopolysaccharidoses (MPSs) are a group of rare inherited metabolic disorders caused by specific lysosomal enzyme deficiencies leading to the sequential degradation of glycosaminoglycans, causing substrate accumulation in various cells and tissues and progressive multiple organ dysfunction. The rare disease medical care team at Mackay Memorial Hospital in Taiwan has been dedicated to the study of MPSs for more than 20 years. Since 1999, more than 50 academic papers focusing on MPSs have been published in international medical journals. Topics of research include the following items regarding MPSs: incidence, natural history, clinical manifestations, gene mutation characteristics, cardiac function, bone mineral density, sleep studies, pulmonary function tests, hearing assessments, percutaneous endoscopic gastrostomy, anesthetic experience, imaging analysis, special biochemical tests, laboratory diagnostics, global expert consensus conferences, prenatal diagnosis, new drug clinical trials, newborn screening, and treatment outcomes. Of these published academic research papers, more than half were cross-domain, cross-industry, and international studies with results in cooperation with experts from European, American and other Asian countries. A cross-specialty collaboration platform was established based on high-risk population screening criteria with the acronym "BECARE" (Bone and joints, Eyes, Cardiac and central nervous system, Abdomen and appearance, Respiratory system, and Ear, nose, and throat involvement). Through this platform, orthopedic surgeons, rheumatologists, ophthalmologists, cardiologists, rehabilitation physicians, gastroenterologists, otorhinolaryngologists, and medical geneticists have been educated with regards to awareness of suspected cases of MPSs patients to allow for a further confirmative diagnosis of MPSs. Because of the progressive nature of the disease, an early diagnosis and early multidisciplinary therapeutic interventions including surgery, rehabilitation programs, symptom-based treatments, hematopoietic stem cell transplantation, and enzyme replacement therapy, are very important.

Keywords

References

  1. Neufield EF, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet AL, Valle D, Sly WS, editors. The metabolic and molecular bases of inherited disease, Vol. 136, 8th edn. New York, NY: McGraw-Hill, 2001, p. 3421-52.
  2. Chuang CK, Lin SP. Neurochemical changes and therapeutical approaches in mucopolysaccharidoses. In: Sankar Surendran, Michael Aschner, Maheep Bhatnagar, editors. Neurochemistry of Metabolic Diseases-Lysosomal storage diseases, phenylketouria and Canavan disease. Transworld Research Network, 2007:1-20.
  3. Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A 2009;149A:960-4. https://doi.org/10.1002/ajmg.a.32781
  4. Chuang CK, Lin SP, Lee SJ, Wang TJ. MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in sanfilippo and morquio syndromes. J Clin Lab Anal 2002;16:253-8. https://doi.org/10.1002/jcla.10051
  5. Chuang CK, Lin SP, Chung SF. Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis. Zhonghua Yi Xue Za Zhi (Taipei) 2001;64:15-22.
  6. Lin SP, Chang JH, Lee-Chen GJ, Lin DS, Lin HY, Chuang CK. Detection of Hunter syndrome (mucopolysaccharidosis type II) in Taiwanese: biochemical and linkage studies of the iduronate-2-sulfatase gene defects in MPS II patients and carriers. Clin Chim Acta 2006;369:29-34. https://doi.org/10.1016/j.cca.2006.01.001
  7. Lee-Chen GJ, Lin SP, Tang YF, Chin YW. Mucopolysaccharidosis type I: characterization of novel mutations affecting alpha-L-iduronidase activity. Clin Genet 1999;56:66-70. https://doi.org/10.1034/j.1399-0004.1999.560109.x
  8. Lee-Chen GJ, Lin SP, Chen IS, Chang JH, Yang CW, Chin YW. Mucopolysaccharidosis type I: Identification and characterization of mutations affecting alpha-L-iduronidase activity. J Formos Med Assoc 2002;101:425-8.
  9. Teng YN, Wang TR, Hwu WL, Lin SP, Lee-Chen GJ. Identification and characterization of -3c-g acceptor splice site mutation in human alpha-L-iduronidase associated with mucopolysaccharidosis type IH/S. Clin Genet 2000;57:131-6.
  10. Chang JH, Lee-Chen GJ, Lin SP, Chuang CK. Characterization of a novel p.S305P and a known c.1006+5G>C splice site mutation in human iduronate-2-sulfatase associated with mucopolysaccharidosis type II. Clin Chim Acta 2007;384:167-70. https://doi.org/10.1016/j.cca.2007.06.014
  11. Lee-Chen GJ, Lin SP, Ko MH, Chuang CK, Chen CP, Lee HH, et al. Identification and characterization of mutations underlying Sanfilippo syndrome type A (mucopolysaccharidosis type IIIA). Clin Genet 2002;61:192-7. https://doi.org/10.1034/j.1399-0004.2002.610304.x
  12. Lee-Chen GJ, Lin SP, Lin SZ, Chuang CK, Hsiao KT, Huang CF, et al. Identification and characterisation of mutations underlying Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB). J Med Genet 2002;39:E3. https://doi.org/10.1136/jmg.39.2.e3
  13. Yang CF, Tsai FJ, Lin SP, Lee CC, Wu JY. A novel in-frame deletion mutation (c106-111del) identified in a Taiwan Chinese patient with type IVA mucopolysaccharidosis. Hum Mutat 2001;18:254. https://doi.org/10.1002/humu.1187
  14. Yang CF, Wu JY, Lin SP, Tsai FJ. Mucopolysaccharidosis type VI: report of two Taiwanese patients and identification of one novel mutation. J Formos Med Assoc 2001;100:820-3.
  15. Lin WD, Lin SP, Wang CH, Hwu WL, Chuang CK, Lin SJ, et al. Genetic analysis of mucopolysaccharidosis type VI in Taiwanese patients. Clin Chim Acta 2008;394:89-93. https://doi.org/10.1016/j.cca.2008.04.014
  16. Chuang CK, Lin HY, Wang TJ, Tsai CC, Liu HL, Lin SP. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis 2014;9:135. https://doi.org/10.1186/s13023-014-0135-3
  17. Chuang CK, Lin HY, Lin SP. Keratanase II digestion accompanied with a liquid chromatography/tandem mass spectrometry for urinary keratan sulfate quantitative analysis. J Mucopolysacch Rare Dis 2017;3:20-7.
  18. Lin HY, Chen MR, Chuang CK, Chen CP, Lin DS, Chien YH, et al. Enzyme replacement therapy for mucopolysaccharidosis VI-experience in Taiwan. J Inherit Metab Dis 2010;33 Suppl 3:S421-7.
  19. Lin HY, Chuang CK, Wang CH, Chien YH, Wang YM, Tsai FJ, et al. Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: a case series. Mol Genet Metab Rep 2016;7:63-9. https://doi.org/10.1016/j.ymgmr.2016.04.003
  20. Lin HY, Chuang CK, Chen MR, Lin SM, Hung CL, Chang CY, et al. Effects of enzyme replacement therapy on cardiac structure and function in patients with mucopolysaccharidoses I, II, IVA and VI. Mol Genet Metab 2016;117:431-7. https://doi.org/10.1016/j.ymgme.2016.02.003
  21. Lin HY, Lin SP, Chuang CK, Chen MR, Chen BF, Wraith JE. Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report. J Inherit Metab Dis 2005;28:1146-8. https://doi.org/10.1007/s10545-005-0211-x
  22. Lin HY, Chuang CK, Chen MR, Chiu PC, Ke YY, Niu DM, et al. Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. Orphanet J Rare Dis 2014;9:21. https://doi.org/10.1186/1750-1172-9-21
  23. Lin HY, Chuang CK, Huang YH, Tu RY, Lin FJ, Lin SJ, et al. Causes of death and clinical characteristics of 34 patients with mucopolysaccharidosis II in Taiwan from 1995-2012. Orphanet J Rare Dis 2016;11:85. https://doi.org/10.1186/s13023-016-0471-6
  24. Lin SP, Shih SC, Chuang CK, Lee KS, Chen MR, Niu DM, et al. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses---changes with age and treatment. Pediatr Pulmonol 2014;49:277-84. https://doi.org/10.1002/ppul.22774
  25. Chen MR, Lin SP, Hwang HK, Yu CH. Cardiovascular changes in mucopolysaccharidoses in Taiwan. Acta Cardiol 2005;60:51-3. https://doi.org/10.2143/AC.60.1.2005049
  26. Lin SM, Lin HY, Chuang CK, Lin SP, Chen MR. Cardiovascular abnormalities in Taiwanese patients with mucopolysaccharidosis. Mol Genet Metab 2014;111:493-8. https://doi.org/10.1016/j.ymgme.2014.02.009
  27. Lin HY, Chen MR, Lin CC, Chen CP, Lin DS, Chuang CK, et al. Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr Pulmonol 2010;45:1205-12. https://doi.org/10.1002/ppul.21309
  28. Lin HY, Shih SC, Chuang CK, Lee KS, Chen MR, Lin HC, et al. Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses. Mol Genet Metab 2014;111:533-8. https://doi.org/10.1016/j.ymgme.2014.02.003
  29. Lin HY, Shih SC, Chuang CK, Chen MR, Niu DM, Lin SP. Assessment of bone mineral density by dual energy X-ray absorptiometry in patients with mucopolysaccharidoses. Orphanet J Rare Dis 2013;8:71. https://doi.org/10.1186/1750-1172-8-71
  30. Chen CP, Lin SP, Tzen CY, Hwu WL, Chern SR, Chuang CK, et al. Prenatal diagnosis and genetic counseling of mucopolysaccharidosis type II (Hunter syndrome). Genet Couns 2007;18:49-56.
  31. Shih SL, Lee YJ, Lin SP, Sheu CY, Blickman JG. Airway changes in children with mucopolysaccharidoses. Acta Radiol 2002;43:40-3.
  32. Chan YL, Lin SP, Man TT, Cheng CR. Clinical experience in anesthetic management for children with mucopolysaccharidoses: report of ten cases. Acta Paediatr Taiwan 2001;42:306-8.
  33. Lin HY, Chuang CK, Chang JH, Lin SP. Early diagnosis for mucopolysaccharidosis I - a 6-month-old female infant presenting with gibbus, hirsutism and mongolian spots in a well baby clinic. J Mucopolysacch Rare Dis 2016;2:23-6. https://doi.org/10.19125/jmrd.2016.2.1.23
  34. Lin HY, Chuang CK, Chiu HC, Lin SP. Mucopolysaccharidosis type II-an unexpected "3 in 1" family. Pediatr Neonatol 2016;57;359-60. https://doi.org/10.1016/j.pedneo.2015.11.005
  35. Lin HY, Lo CI, Chuang CK, Lin SP. Mucopolysaccharidosis I (Scheie syndrome) - a rare cause of severe aortic stenosis in a 31-year-old man. J Formos Med Assoc 2015;114:1015-6. https://doi.org/10.1016/j.jfma.2014.05.009
  36. Lin HY, Chuang CK, Lee KS, Lin SP. Awareness of mucopolysaccharidosis in an otorhinolaryngologic clinic. Pediatr Neonatol 2017;58:198-9. https://doi.org/10.1016/j.pedneo.2016.12.004
  37. Lin HY, Chuang CK, Liu SC, Lin SP. Awareness of attenuated mucopolysaccharidoses in a pediatric orthopedic clinic. Pediatr Neonatol 2018.
  38. Bhattacharya K, Balasubramaniam S, Choy Y, Fietz M, Fu A, Jin D, et al. Overcoming the barriers to diagnosis of Morquio A syndrome. Orphanet J Rare Dis 2014;9:192. https://doi.org/10.1186/s13023-014-0192-7
  39. Choy YS, Bhattacharya K, Balasubramaniam S, Fietz M, Fu A, Inwood A, et al. Identifying the need for a multidisciplinary approach for early recognition of mucopolysaccharidosis VI (MPS VI). Mol Genet Metab 2015;115:41-7. https://doi.org/10.1016/j.ymgme.2015.03.005
  40. Lin SP, Lin HY, Wang TJ, Chang CY, Lin CH, Huang SF, et al. A pilot newborn screening program for mucopolysaccharidosis type I in Taiwan. Orphanet J Rare Dis 2013;8:147. https://doi.org/10.1186/1750-1172-8-147
  41. Chuang CK, Lin HY, Wang TJ, Huang SF, Lin SP. Bio-Plex immunoassay measuring the quantity of lysosomal Nacetylgalactosamine-6-sulfatase protein in dried blood spots for mucopolysaccharidosis IVA newborn screening purpose. BMJ Open 2017;7:e014410. https://doi.org/10.1136/bmjopen-2016-014410
  42. Lin HY, Chuang CK, Lin SP. Newborn screening for lysosomal storage diseases in Taiwan. J Mucopolysacch Rare Dis 2017;3:14-9.
  43. Jones SA, Almássy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al.; HOS Investigators. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 2009;32:534-43. https://doi.org/10.1007/s10545-009-1119-7
  44. Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R, et al. The morquio a clinical assessment program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab 2013;109:54-61. https://doi.org/10.1016/j.ymgme.2013.01.021
  45. de Ru MH, Teunissen QG, van der Lee JH, Beck M, Bodamer OA, Clarke LA, et al. Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure. Orphanet J Rare Dis 2012;7:22. https://doi.org/10.1186/1750-1172-7-22
  46. Hwu WL, Okuyama T, But WM, Estrada S, Gu X, Hui J, et al. Current diagnosis and management of mucopolysaccharidosis VI in the Asia-Pacific region. Mol Genet Metab 2012;107:136-44. https://doi.org/10.1016/j.ymgme.2012.07.019